{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:22:28Z","timestamp":1791829348483,"version":"4.3.4"},"reference-count":14,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the efficacy and safety of pembrolizumab plus chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible participants had histologically confirmed extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer, unresectable locally advanced or metastatic disease measurable per RECIST v1.1, known HBV and HCV status (including active HBV), and Eastern Cooperative Oncology Group performance status 0 or 1. Participants were randomly assigned 1:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks for \u226435 cycles plus gemcitabine and cisplatin. HBV-positive participants were monitored for HBV reactivation, and antiviral therapy was required for chronic HBV infection. The primary end point was OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The intention-to-treat population comprised 1,069 participants (533, pembrolizumab group; 536, placebo group). The median time from randomization to data cutoff (November 14, 2023) was 36.6 months (range, 29.2\u201349.4). Among 329 HBV-positive participants (30.8%), 30 had chronic and 299 had clinically resolved HBV. The OS HR was 0.87 [95% confidence interval (CI), 0.69\u20131.10] with pembrolizumab versus placebo for the HBV-positive subgroup and 0.85 (95% CI, 0.73\u20130.99) for the HBV-negative subgroup. Safety was consistent between the subgroups. Eight participants had HBV reactivation (5, pembrolizumab group; 3, placebo group), and no cases of HBV-associated hepatitis occurred in either group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Efficacy and safety outcomes were consistent between HBV-positive and HBV-negative participants receiving first-line pembrolizumab compared with placebo plus gemcitabine and cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0633","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:32:35Z","timestamp":1772188355000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00t33hh48","id-type":"ROR","asserted-by":"publisher"}],"name":"The Chinese University of Hong Kong 1 State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Y.K. Pao Centre for Cancer, , Hong Kong, Hong Kong SAR, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-0305","authenticated-orcid":false,"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02zhqgq86","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Hong Kong 2 , Hong Kong, Hong Kong SAR, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, San Francisco 3 , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-2126","authenticated-orcid":false,"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, Los Angeles 4 , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[{"name":"5Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-6117","authenticated-orcid":false,"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"6Kyorin University Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-6761","authenticated-orcid":false,"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[{"name":"7Zhongshan Hospital Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-1823","authenticated-orcid":false,"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[{"name":"8University Medical Center, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-1970","authenticated-orcid":false,"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bv64a69","id-type":"ROR","asserted-by":"publisher"}],"name":"The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) 9 , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-2737","authenticated-orcid":false,"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Oncology and Cancer Immunology, Charite Campus Mitte, Freie Universit\u00e4t Berlin, Humboldt Universit\u00e4t zu Berlin, Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7432","authenticated-orcid":false,"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[{"name":"11Izmir Economy University Medical Point Hospital, Karsiyaka, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-2612","authenticated-orcid":false,"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[{"name":"12Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01yezas83","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Eug\u00e8ne Marquis 13 , Rennes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fp9z389","id-type":"ROR","asserted-by":"publisher"}],"name":"Cholangiocarcinoma Foundation 14 , Salt Lake City, Utah."},{"name":"15Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":false,"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00aapa202","id-type":"ROR","asserted-by":"publisher"}],"name":"Kanagawa Cancer Center 16 , Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 17 Division of Gastroenterology and Hepatology, Medical Oncology, Toronto General Hospital, , University of Toronto, Toronto, Canada."},{"name":"18Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1664-381X","authenticated-orcid":false,"given":"Liis","family":"Starkopf","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02891sr49","id-type":"ROR","asserted-by":"publisher"}],"name":"Merck & Co., Inc. 19 , Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3184-9605","authenticated-orcid":false,"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02891sr49","id-type":"ROR","asserted-by":"publisher"}],"name":"Merck & Co., Inc. 19 , Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5523-2807","authenticated-orcid":false,"given":"Abby B.","family":"Siegel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02891sr49","id-type":"ROR","asserted-by":"publisher"}],"name":"Merck & Co., Inc. 19 , Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-1521","authenticated-orcid":false,"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[{"name":"20Nanjing Tianyinshan Hospital of China Pharmaceutical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2026031701583778100_bib1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3748\/wjg.v28.i21.2251","article-title":"Viral hepatitis and hepatocellular carcinoma: from molecular pathways to the role of clinical surveillance and antiviral treatment","volume":"28","author":"Stella","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2026031701583778100_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13027-022-00457-9","article-title":"Hepatitis B and C virus infections and the risk of biliary tract cancers: a meta-analysis of observational studies","volume":"17","author":"Wang","year":"2022","journal-title":"Infect Agents Cancer"},{"key":"2026031701583778100_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32135","article-title":"Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas","volume":"75","author":"An","year":"2022","journal-title":"Hepatology"},{"key":"2026031701583778100_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36401\/JIPO-23-28","article-title":"Management of hepatitis B virus and hepatitis C virus infections in patients with cancer receiving immune checkpoint inhibitors","volume":"7","author":"Mustafayev","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"2026031701583778100_bib5","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026031701583778100_bib6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2026031701583778100_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2026031701583778100_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2025.03.019","article-title":"Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study","volume":"83","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"issue":"16_suppl","key":"2026031701583778100_bib9","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031701583778100_bib10","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026031701583778100_bib11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"issue":"16_suppl","key":"2026031701583778100_bib12","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2024.42.16_suppl.4097","article-title":"Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) for advanced biliary tract cancer (BTC)","volume":"42","author":"Yau","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031701583778100_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/JHC.S363123","article-title":"Antiviral treatments eliminate the adverse impacts of high baseline HBV loads on the survival of HBV-related HCC patients","volume":"9","author":"Hu","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"2026031701583778100_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40264-024-01399-4","article-title":"Consensus guidelines: best practices for the prevention, detection and management of hepatitis B virus reactivation in clinical trials with immunosuppressive\/immunomodulatory therapy","volume":"47","author":"Cohen","year":"2024","journal-title":"Drug Saf"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0633\/3743687\/crc-25-0633.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/577\/3748049\/crc-25-0633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/577\/3748049\/crc-25-0633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:58:47Z","timestamp":1773727127000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/577\/775295\/Impact-of-Hepatitis-B-Virus-Infection-on-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0633","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31770200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770203","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770194","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31770197","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8355158","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}